|
|
|
| Effect of platelet-derived growth factor-C on proliferation and migration of ovarian cancer cells in vitro |
| LI Xiaoying1, GUO Ximin2,GUO Hongyan2, and PAN Lingya1 |
1.Department of Obstetrics and Gynecology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences ＆ Peking Union Medical College,Beijing 100730,China;
2.Department of Advanced Interdisciplinary Studies, Institute of Basic Medical Sciences, Beijing 100850, China;
3.Department of Dentistry,General Hospital of Chinese People’s Armed Police Force,Beijing 100039,China |
|
|
|
|
Abstract Objective To examine the effect of platelet-derived growth factor-C (PDGF-C) on ovarian clear cell carcinoma cells ES-2 in vitro.Methods ES-2 cells were cultured with the supplement of different concentrations of PDGF-C (0, 10, 20 and 40 μg/L). CCK8 assay was used to detect the effect of PDGF-C on cell proliferation. Flow cytometry was used to detect cell cycle phases. Transwell assay and cell scratch test were used to detect cell migration ability.Results PDGF-C could not only significantly induce proliferation of ES-2 compared with the blank control group without PDGF-C, but increase the percentage of the cells in S phase. Additionally, it was found the best concentration of PDGF-C to promote the proliferation of ES-2 cells was 20 μg/L. With the stimulation of different concentrations of PDGF-C, the proportion of ES-2 cells in G1 and S cell cycle was significantly decreased (P<0.05) and significantly increased (P<0.05) respectively, while the proportion of cells in G2 + M phase did not change compared with the control group (P>0.05). At the same time, PDGF-C increased the migration ability of ES-2 cells.Conclusions PDGF-C can promote the proliferation and migration of ES-2 cells in vitro.
|
|
Received: 04 August 2016
|
|
|
|
|
|
| [1] |
Rooth C. Ovarian cancer: risk factors,treatment and management [J]. Br J Nurs,2013,22 (17) : S23-30.
|
| [2] |
Collins Y, Holcomb K,Chapman-Davis E,et al. Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology [J]. Gynecol Oncol,2014,133(2):353-361.
|
| [3] |
Lee Y Y, Kim T J, Kim M J, et al.Prognosis of ovarian clear cell carcinoma compared toother histological subtypes: a meta-analysis [J]. Gynecol Oncol, 2011, 122(3): 541-547.
|
| [4] |
SugiyamaT, KamuraT, Kigawa N, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy [J]. Cancer, 2000, 88: 2584-2589.
|
| [5] |
Lai K K, Shang S, Lohia N, et al. Extracellular matrix dynamics in hepatocarcinogenesis: a comparative proteomics study of PDGFC transgenic and Pten null mouse models [J]. PLoS Genet, 2011, 7(6): e1002147.
|
| [6] |
Khajah M A, Al S S, Mathew P M, et al. Differential effect of growth factors on invasion and proliferation of endocrine resistant breast cancer cells[J]. PLoS One, 2012, 7(7):e41847.
|
| [7] |
Ruffini F, Tentori L, Dorio A S, et al. Platelet-derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness [J]. Oncol Rep, 2013, 30(6):2887-2896.
|
| [8] |
Vera C,Tapia V,Vega M,et al.Role of nerve growth factor and its TRKA receptor in normal ovarian and epithelial ovarian cancer angio genesis [J]. J Ovarian Res,2014, 7: 82.
|
| [9] |
McCormack D R,Walsh A J,Sit W,et al. In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts [J]. Biomed Opt Express,2014, 5(7) : 2247-2261.
|
| [10] |
Neto J S, Kho R M, Siufi D F D S, et al. Cellular, Histologic, and Molecular Changes Associated With Endometriosis and Ovarian Cancer [J]. Journal of Minimally Invasive Gynecology, 2014, 21(1): 55~63.
|
| [11] |
Sun Y. Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures [J]. Med Res Rev, 2015, 35(2):408-436.
|
| [12] |
Frings O, Augsten M, Tobin N P, et al. Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling [J]. Am J Pathol, 2013, 182(6): 2037-2047.
|
| [13] |
Uutela M, Lauren J, Bergsten E, et al. Chromosomal location, exon structure, and vascular expression patterns of the human PDGF-C and PDGF-D genes [J]. Circulation, 2001, 103(18): 2242-2247.
|
| [14] |
Savikko J, Teppo A M, Taskinen E, et al. Different effects of tacrolimus and cyclosporine on PDGF induction and chronic allograft injury: evidence for improved kidney graft outcome [J]. Transpl Immunol, 2014, 31(3): 145-151.
|
| [15] |
Demaria M, Ohtani N, Youssef S A, et al. An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA [J]. Dev Cell, 2014, 31(6): 722-733.
|
| [16] |
Guo J, Li L, Wu Y J, et al. Inhibitory effects of Brazilin on the vascular smooth muscle cell proliferation and migration induced by PDGF-BB [J]. Am J Chin Med, 2013, 41(6): 1283-1296.
|
| [17] |
Bonner J C. Regulation of PDGF and its receptors in fibrotic diseases [J]. Cytokine Growth Factor Rev, 2004, 15(4): 255-273.
|
| [18] |
Martin I V, Borkham-Kamphorst E, Zok S, et al. Platelet-derived growth factor (PDGF)-C neutralization reveals differential roles of PDGF receptors in liver and kidney fibrosis [J]. Am J Pathol, 2013, 182(1): 107-117.
|
| [19] |
Grun K, Markova B, Bohmer F D, et al. Elevated expression of PDGF-C in coxsackievirus B3-induced chronic myocarditis [J]. Eur Heart J, 2005, 26(7): 728-739.
|
| [20] |
Li R, Maminishkis A, Wang F E, et al. PDGF-C and -D induced proliferation/migration of human RPE is abolished by inflammatory cytokines [J]. Invest Ophthalmol Vis Sci, 2007, 48(12): 5722-5732.
|
| [21] |
Campbell J S, Hughes S D, Gilbertson D G, et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma [J]. Proc Natl Acad Sci USA, 2005, 102(9): 3389-3394.
|
|
|
|
2017, Vol. 28 
